No data to show
XTSE
APLI
Market cap1mUSD
Jun 10, Last price
0.02CAD
1D
0.00%
1Q
-57.14%
IPO
-98.00%
Name
Appili Therapeutics Inc
Chart & Performance
P/E
—
P/S
2.20
EPS
—
Div Yield, %
—
Shrs. gr., 5y
31.98%
Rev. gr., 5y
%
Revenues
827k
+147.60%
Net income
-4m
L-59.09%
CFO
-2m
L-75.59%
Earnings
Jun 23, 2025
Profile
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||
Revenues | 827 147.60% | 334 -75.97% | ||||||
Cost of revenue | 8,813 | 8,441 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (7,986) | (8,106) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 70 | 36 | ||||||
Tax Rate | ||||||||
NOPAT | (8,055) | (8,143) | ||||||
Net income | (3,781) -59.09% | (9,243) -63.20% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 3,214 | |||||||
BB yield | -70.65% | |||||||
| Debt | ||||||||
Debt current | 7,310 | 113 | ||||||
Long-term debt | 875 | 7,552 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | (7,552) | |||||||
Net debt | 8,090 | 5,199 | ||||||
| Cash flow | ||||||||
Cash from operating activities | (2,464) | (10,098) | ||||||
CAPEX | (30) | (3) | ||||||
Cash from investing activities | (29) | (3) | ||||||
Cash from financing activities | 122 | 5,908 | ||||||
FCF | (5,348) | (8,115) | ||||||
| Balance | ||||||||
Cash | 94 | 2,466 | ||||||
Long term investments | ||||||||
Excess cash | 53 | 2,449 | ||||||
Stockholders' equity | (26,770) | (13,810) | ||||||
Invested Capital | 24,030 | 14,037 | ||||||
ROIC | ||||||||
ROCE | 291.45% | |||||||
| EV | ||||||||
Common stock shares outstanding | 121,266 | 113,732 | ||||||
Price | 0.04 -12.50% | 0.04 -66.67% | ||||||
Market cap | 4,244 -6.70% | 4,549 -43.19% | ||||||
EV | 12,335 | 9,749 | ||||||
EBITDA | (7,972) | (8,100) | ||||||
EV/EBITDA | ||||||||
Interest | 1,631 | 1,096 | ||||||
Interest/NOPBT | ||||||||